Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 6:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 176 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Antihypertensive treatment Clear all
Completed Phase 2 Interventional

Preventing Recurrence of Thromboembolic Events Through Coordinated Treatment in the District of Columbia

NCT00703274
View directory record Official record
Conditions
Stroke
Interventions
PROTECT DC
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
6
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Results available

Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

NCT01558661
View directory record Official record
Conditions
Adenoid Cystic Carcinoma
Interventions
AG-013736 (AXITINIB)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Not applicable Interventional

An Evaluation of Clinical Pharmacist-led Intervention on Clinical Outcomes in Patients With Ischemic Stroke

NCT01876667
View directory record Official record
Conditions
Stroke
Interventions
Intervention (CPCRS) Group, Placebo
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 85 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Results available

Blood Pressure After Endovascular Stroke Therapy-II

NCT04116112
View directory record Official record
Conditions
Acute Stroke, Endovascular Thrombectomy
Interventions
Nicardipine, Labetalol, Hydralazine
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Hartford, Connecticut • Cincinnati, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 3 Interventional

A Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Hypertension

NCT00200434
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 20, 2005 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

NCT00696384
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan medoxomil, Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications., Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
33
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2012 · Synced Oct 5, 2026, 6:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hypertension, Brain Clearance, and Markers of Neurodegeneration

NCT05785871
View directory record Official record
Conditions
Mild Cognitive Impairment, Hypertension
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 2Phase 3 Interventional

African American Study of Kidney Disease and Hypertension ABPM Pilot Study

NCT00582777
View directory record Official record
Conditions
Hypertensive Renal Disease
Interventions
USUAL - take your BP Meds as you usually do, HS DOSING, ADD On Dosing
Behavioral · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension

NCT01049009
View directory record Official record
Conditions
High Blood Pressure
Interventions
Nebivolol, Metoprolol XL
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 80 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 3 Interventional

DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension

NCT00389779
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan, Guanfacine, Darusentan Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
849 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
87
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 5, 2026, 6:19 PM EDT
Recruiting Not applicable Interventional

StrokeNet Thrombectomy Endovascular Platform

NCT06289985
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Endovascular thrombectomy with any FDA-approved category POL or NRY device, Medical Management
Device · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
41
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Not applicable Interventional Results available

Addressing Antihypertensive Medication Adherence Through EHR-enabled Teamlets in Primary Care

NCT05349422
View directory record Official record
Conditions
Blood Pressure, Medication Adherence
Interventions
Electronic Health Record (EHR) Enabled Teamlets
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
1,842 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 5, 2026, 6:19 PM EDT
Completed No phase listed Observational

Effects of Chronic Antihypertensive Therapy on Clinical Outcomes in Septic Shock

NCT02876341
View directory record Official record
Conditions
Atrial Fibrillation, Septic Shock
Interventions
Not listed
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 5, 2026, 6:19 PM EDT
Completed No phase listed Observational

A Real-world Study of the Safety of Hypertension Medication Therapy in Japanese Patients With Naïve Hypertension

NCT06683768
View directory record Official record
Conditions
Hypertension
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40,563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 5, 2026, 6:19 PM EDT
Terminated Phase 3 Interventional Results available

Hypertension in Hemodialysis Patients (Aim 3)

NCT00582114
View directory record Official record
Conditions
Hemodialysis, Hypertension, Left Ventricular Hypertrophy
Interventions
Lisinopril, Atenolol
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 5, 2026, 6:19 PM EDT
Completed No phase listed Observational

Genetics of Hypertension Associated Treatments (GenHAT)

NCT00006294
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Hypertension, Coronary Disease, Myocardial Infarction
Interventions
Chlorthalidone, Lisinopril, Amlodipine, Doxazosin
Drug
Lead sponsor
Donna Arnett, 257-5678
Other
Eligibility
55 Years and older
Enrollment
37,939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Results available

Blood Pressure Lowering in Dialysis (BOLD) Trial

NCT03459807
View directory record Official record
Conditions
Blood Pressure, End Stage Renal Disease on Dialysis (Diagnosis), Chronic Kidney Diseases, Chronic Kidney Disease Stage 5
Interventions
Anti-Hypertensive medications, Dry Weight Adjustment
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
San Francisco, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 5, 2026, 6:19 PM EDT
Recruiting Phase 3 Interventional

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

NCT07181109
View directory record Official record
Conditions
High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
Interventions
Zilebesiran, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
11,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
270
States / cities
Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 214 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Not applicable Interventional Results available

SPYRAL PIVOTAL - SPYRAL HTN-OFF MED Study

NCT02439749
View directory record Official record
Conditions
Hypertension, Vascular Diseases, Cardiovascular Diseases
Interventions
Symplicity Spyral™ multi-electrode renal denervation system, Sham Procedure
Device · Procedure
Lead sponsor
Medtronic Vascular
Industry
Eligibility
20 Years to 80 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
30
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 5, 2026, 6:19 PM EDT
Recruiting Phase 2 Interventional

A Study of Blood Pressure Control During Cancer Treatment

NCT06023576
View directory record Official record
Conditions
Breast Cancer, Cardiotoxicity
Interventions
antihypertensive medications, Blood pressure measurement, Echocardiogram, Symptom-limited cardiopulmonary exercise test, Quality of Life Measures, Biomarkers
Other · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Mineralocorticoid Receptor (MR) Antagonist (Eplerenone) vs Amlodipine and STRIATIN

NCT03683069
View directory record Official record
Conditions
Hypertension, Genetics Hypertension
Interventions
Eplerenone vs Amlodipine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 4 Interventional Results available

Chronic Hypertension and Pregnancy (CHAP) Project

NCT02299414
View directory record Official record
Conditions
Hypertension
Interventions
Anti-hypertensive therapy, No anti-hypertensive therapy (unless BP is severe)
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
12 Years and older · Female only
Enrollment
2,408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
72
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Not applicable Interventional Results available

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

NCT01471522
View directory record Official record
Conditions
Cardiovascular Diseases, Coronary Disease, Coronary Artery Disease, Heart Diseases, Myocardial Ischemia
Interventions
cardiac catheterization, coronary artery bypass graft surgery, percutaneous coronary intervention, Lifestyle, Medication
Procedure · Behavioral · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
5,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
109
States / cities
Birmingham, Alabama • Yuma, Arizona • Beverly Hills, California + 82 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 5, 2026, 6:19 PM EDT